Influx Health, a company in the Pharmaceuticals industry, reported revenue of ₹85 crore and net profit of ₹12 crore for the September 2026 quarter.
Influx Health. (NSE: INFLUX-SM) closed at ₹285.00 on 20 Nov 2026, up 20.6% over the past year. Its market capitalisation is ₹660 crore and it trades at 29.2 times earnings.
Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.